Friday, 15 Dec 2017

You are here

The RheumNow Week in Review – 4 August 2017

Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on RheumNow.com. 

  1. Amgen submitted its Biologic Licence application to the FDA for Denosumab in Rx of Glucorticoid induced Osteoporosis https://t.co/MdKOssFggV
  2. 165 scleroderma pts double pos for centromere & anti–IFI-16 Abs incr. risk for digital vascular events, >3 fold higher odds of Severe Raynauds https://t.co/ueOuUC7R2O  
  3. IBD clinic study shows CT-Dx sacroiliitis found in 15% of 233 Crohns, 16.9%, of 83 UC pts & 5.6% 108 controls https://t.co/O2WuJoUPL6
  4. Among 608 SSc pts 3% developed Scl renal crisis - risk w/ digital gangrene, pred >15, alb <3, cardiac involvement https://t.co/R6HpDSbk3R
  5. Hospitalizationsfor Serious infections increased from 90 to 206  per 100,000 PY from 1993-2013. Sepsis tripled. But pneumonia, UTI & OIs decreased https://t.co/rHL5pJHMSc
  6. No Increase in Malformations with Etanercept Use During Pregnancy
  7. Lupus Hospitalizations are Common 
  8. Arthritis Advisory Panel Votes Down Sirukumab  
  9. FDA Arthritis Advisory Panel Endorses Tofacitinib Approval for Psoriatic Arthritis 
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 15 December 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com. 

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations.